{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Rein Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"RNTX"},"Address":{"label":"Address","value":"285 SUMMER STREET,UNIT 101, BOSTON, Massachusetts, 02210, United States"},"Phone":{"label":"Phone","value":"+1 617 995-0900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis)."},"CompanyUrl":{"label":"Company Url","value":"https://www.reintx.com"}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}